Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes

Journal of General Virology

Volumn 91, Issue 5, 2010, Pages 1189-1193

  Chatterji, Udayan ^a   Bobardt, Michael D ^a   Lim, Precious ^a   Gallay, Philippe A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN A; ISOMERASE; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PROTEINASE;

ARTICLE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN LOCALIZATION; VIRUS REPLICATION;

CELL LINE; CYCLOPHILIN A; HEPACIVIRUS; HEPATOCYTES; HUMANS; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

HEPATITIS C VIRUS;

EID: 77951051950     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.018531-0     Document Type: Article

References (29)

1. Appel, N., Schaller, T., Penin, F. & Bartenschlager, R. (2006). From structure to function: new insights into hepatitis C virus RNA replication. J Biol Chem 281, 9833-9836. (Pubitemid 43864513)
2. Azouzi, S., El Kirat, K. & Morandat, S. (2010). The potent antimalarial drug cyclosporin A preferentially destabilizes sphingomyelin-rich membranes. Langmuir 26, 1960-1965.
3. Chatterji, U., Bobardt, M., Selvarajah, S., Yang, F., Tang, H., Sakamoto, N., Vuagniaux, G., Parkinson, T. & Gallay, P. (2009). The isomerase active site of cyclophilin A is critical for hepatitis C virus replication. J Biol Chem 284, 16998-17005.
4. Chatterji, U., Lim, P., Bobardt, M., Wieland, S., Cordek, D. G., Vuagniaux, G., Chisari, F., Cameron, C. E., Targett-Adams, P., Parkinson, T. & other authors (2010). HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J Hepatol (in press).
5. Coelmont, L., Kaptein, S., Paeshuyse, J., Vliegen, I., Dumont, J.-M., Vuagniaux, G. & Neyts, J. (2009). Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 53, 967-976.
6. Epand, R. M., Epand, R. F. & McKenzie, R. C. (1987). Effects of viral chemotherapeutic agents on membrane properties. Studies of cyclosporin A, benzyloxycarbonyl-D-Phe-L-Phe-Gly and amantadine. J Biol Chem 262, 1526-1529.
7. Fernandes, F., Poole, D. S., Hoover, S., Middleton, R., Andrei, A. C., Gerstner, J. & Striker, R. (2007). Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology 46, 1026-1033. (Pubitemid 350144767)
8. Fischer, G., Wittmann-Liebold, B., Lang, K., Kiefhaber, T. & Schmid, F. X. (1989). Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature 337, 476-478.
9. Flisiak, R., Horban, A., Gallay, P., Bobardt, M., Selvarajah, S., Wiercinska-Drapal, A., Siwak, E., Cielniak, I., Higersberger, J. & other authors (2008). The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 47, 817-826. (Pubitemid 351449673)
10. Flisiak, R., Feinman, S. V., Jablkowski, M., Horban, A., Kryczka, W., Pawlowska, M., Heathcote, J. E., Mazzella, G., Vandelli, C. & other authors (2009). The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 49, 1460-1468.
11. Gallay, P. A. (2009). Cyclophilin inhibitors. Clin Liver Dis 13, 403-417.
12. Goto, K., Watashi, K., Murata, T., Hishiki, T., Hijikata, M. & Shimotohno, K. (2006). Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811. Biochem Biophys Res Commun 343, 879-884.
13. Goto, K., Watashi, K., Inoue, D., Hijikata, M. & Shimotohno, K. (2009). Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor. Cancer Sci 100, 1943-1950.
14. Hanoulle, X., Badillo, A., Wieruszeski, J. M., Verdegem, D., Landrieu, I., Bartenschlager, R., Penin, F. & Lippens, G. (2009). Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B. J Biol Chem 284, 13589-13601.
15. Hopkins, S., Heuman, D., Gavis, E., Lalezari, J., Glutzer, E., DiMasso, B., Rusnak, P., Wring, S., Smitley, S. & Ribeill, Y. (2009). SCY-635 Demonstrates Clinically Relevant Single-agent Results in a Phase 1b Study in Adults with HCV. 44th Annual Meeting of the European Association for the Study of the Liver; Copenhagen, Denmark; Abstr. 89.
16. Ishii, N., Watashi, K., Hishiki, T., Goto, K., Inoue, D., Hijikata, M., Wakita, T., Kato, N. & Shimotohno, K. (2006). Diverse effects of cyclosporine on hepatitis C virus strain replication. J Virol 80, 4510-4520.
17. Kaul, A., Stauffer, S., Berger, C., Pertel, T., Schmitt, J., Kallis, S., Lopez, M. Z., Lohmann, V., Luban, J. & Bartenschlager, R. (2009). Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog 5, e1000546.
18. Liu, Z., Yang, F., Robotham, J.-M. & Tang, H. (2009). Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex. J Virol 83, 6554-6565.
19. Ma, S., Boerner, J. E., TiongYip, C., Weidmann, B., Ryder, N. S., Cooreman, M. P. & Lin, K. (2006). NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon. Antimicrob Agents Chemother 50, 2976-2982. (Pubitemid 44396401)
20. Mathy, J. E., Ma, S., Compton, T. & Lin, K. (2008). Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance. Antimicrob Agents Chemother 52, 3267-3275.
21. Nakagawa, M., Sakamoto, N., Enomoto, N., Tanabe, Y., Kanazawa, T., Koyama, N., Kurosaki, M., Maekawa, S., Yamashiro, T. & other authors (2004). Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 313, 42-47. (Pubitemid 37524022)
22. Paeshuyse, J., Kaul, A., De Clercq, E., Rosenwirth, B., Dumont, J.-M., Scalfaro, P., Bartenschlager, R. & Neyts, J. (2006). The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 43, 761-770.
23. Penin, F., Dubuisson, J., Rey, F. A., Moradpour, D. & Pawlotsky, J.-M. (2004). Structural biology of hepatitis C virus. Hepatology 39, 5-19.
24. Quinkert, D., Bartenschlager, R. & Lohmann, V. (2005). Quantitative analysis of the hepatitis C virus replication complex. J Virol 79, 13594-13605. (Pubitemid 41508172)
25. Robida, J. M., Nelson, H. B., Liu, Z. & Tang, H. (2007). Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol 81, 5829-5840. (Pubitemid 46847020)
26. Watashi, K., Hijikata, M., Hosaka, M., Yamaji, M. & Shimotohno, K. (2003). Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 38, 1282-1288. (Pubitemid 37314838)
27. Watashi, K., Ishii, N., Hijikata, M., Inoue, D., Murata, T., Miyanari, Y. & Shimotohno, K. (2005). Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell 19, 111-122. (Pubitemid 40884662)
28. Yang, F., Robotham, J. M., Nelson, H. B., Irsigler, A., Kenworthy, R. & Tang, H. (2008). Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 82, 5269-5278. (Pubitemid 351705235)
29. Zydowsky, L. D., Etzkorn, F. A., Chang, H. Y., Ferguson, S. B., Stolz, L. A., Ho, S. I. & Walsh, C. T. (1992). Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition. Protein Sci 1, 1092-1099.